Bristol Myers Squibb – Medical Alley Association
Bristol-Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large […]

In The Know: Healthcare News for October 12, 2020

Cleveland Clinic Unveils Top 10 Medical Innovations For 2021 3M survey: Trust in science rises during pandemic Recombinetics Inc. Merges with Makana Therapeutics to Accelerate Xenotransplantation gBETA Medtech Announces Fall 2020 Companies HabitAware receives $1M grant from the National Science Foundation How Medtronic’s new diversity leader wants to make the company even better Meet the […]

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.

MAA COVID-19 INFORMATION DISCLAIMER: The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service.   The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER